Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Samuel Dagogo-JackJie LiuRoy EldorGuillermo AmorinJeremy JohnsonDarcy HilleYuqin LiaoSusan HuyckGregory GolmSteven G TerraJames P MancusoSamuel S EngelBrett LauringPublished in: Diabetes, obesity & metabolism (2017)
Ertugliflozin added to metformin and sitagliptin was well-tolerated, and provided clinically meaningful, durable glycaemic control, BW and SBP reductions vs placebo over 52 weeks.